Nexalin Technology Inc. (NASDAQ: NXL) announced the United States Patent and Trademark Office issued U.S. Patent No. 12,629,519 for its transcranial alternating current dynamic frequency stimulation method targeting anxiety, depression and insomnia.

The patent, titled "Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia," provides intellectual property protection through 2042 for the company's dynamic frequency stimulation technology.

The patent covers methods involving transcranial alternating current stimulation using dynamic frequency stimulation designed for three mental health conditions. Nexalin's Deep Intracranial Frequency Stimulation platform aims to penetrate deeper brain structures associated with neuropsychiatric conditions through non-invasive neuromodulation.

"This patent represents another major milestone for Nexalin and strengthens the defensibility of our long-term platform strategy," said Mark White, Chief Executive Officer of Nexalin Technology. "We believe our DIFS technology has the potential to create an entirely new category of non-invasive, deep-brain, drug-free treatment for patients who need alternatives beyond traditional medications."

The company plans to deliver its treatment through the Nexalin NeuroCare virtual clinic, designed as a physician-supervised model for in-home mental health treatment. The patent builds on Nexalin's intellectual property strategy covering applications across multiple conditions including Alzheimer's disease, traumatic brain injury and PTSD.

Nexalin's Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, Oman and Israel. The company continues developing its HALO Clarity platform and NeuroCare virtual clinic ecosystem, combining neurostimulation hardware with AI-enabled remote patient monitoring and physician oversight.